ACG Inspection’s CEO talks about a ‘fear’ of the disruption caused by advanced medicine, which prevents big pharma companies from investing in the supply chain.
At the BIA’s annual conference, industry executives discussed the UK’s position as a leader in bioprocessing and what steps must be taken to keep pace with global innovation.
Celltrion receives EMA marketing authorisation for Remsima SC, the first subcutaneously-administered option for delivery of infliximab, a treatment for rheumatoid arthritis.
Executives from the largest companies in the industry discuss the increasing prevalence of biologics and the future focus for therapeutics at Pharma Integrates.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
